Guggenheim analyst Yatin Suneja reiterated a Buy rating on Dianthus Therapeutics (NASDAQ: DNTH).The analyst commented: "Today, the Italian pharmaceutical company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE